ym 529 has been researched along with Bone Loss, Osteoclastic in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 9 (45.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Bala, JL; Baron, RA; Błazewska, KM; Coxon, FP; Dunford, JE; Ebetino, FH; Kashemirov, BA; Kirsten, ML; Lundy, MW; Mallard-Favier, I; Marma, MS; McKenna, CE; Rogers, MJ; Rojas, J; Seabra, MC; Stewart, CA | 1 |
| Hongo, M; Ishikawa, Y; Kasukawa, Y; Kudo, D; Miyakoshi, N; Shimada, Y | 1 |
| Fukushima, S; Kimoto, A; Mori, H; Mori, M; Nakamura, T; Nozaki, K; Shiroya, T; Tanaka, M | 1 |
| Ichigo, S; Imai, A; Matsunami, K; Takagi, H | 1 |
| Hosoya, A; Kayasuga, R; Mori, H; Nakamura, H; Ozawa, H; Tanaka, M | 1 |
| Aoyama, K; Kimoto, A; Minamide, T; Miyata, K; Mori, H; Mori, M; Nozaki, K; Sasamata, M; Shimizu, K; Shimokawa, K; Suzuki, H; Tanaka, M; Usui, T; Yamamotoya, H | 1 |
| Fukunaga, M; Hagino, H; Matsumoto, T; Nakamura, T; Nakano, T; Ohashi, Y; Shiraki, M; Takaoka, K | 1 |
| Okamoto, K; Okimoto, N; Sakai, A; Yoshioka, T | 1 |
| Inazu, M; Ito, T; Kambe, F; Kanda, K; Kawano, S; Kurokouchi, K; Ohmori, S; Seo, H | 1 |
| Inazu, M; Ito, T; Iwata, H; Izumi, R; Kanda, K; Kurokouchi, K; Murata, Y; Ohmori, S; Seo, H | 1 |
| Inazu, M; Ito, T; Iwata, H; Izumi, R; Kanda, K; Kurokouchi, K; Murata, Y; Ohmori, S; Seo, H; Yasukawa, K | 1 |
| Goto, H; Kanematsu, T; Miki, T; Muguruma, H; Sone, S; Uehara, H; Yano, S; Zhang, H | 1 |
| Chatani, Y | 1 |
| Cui, N; Guo, C; Hashimoto, S; Noma, H; Nomura, T; Okamoto, M; Sato, M; Shibahala, T; Takagi, R; Yokoo, K; Yu, G | 1 |
| Fukata, S; Furihata, M; Inoue, K; Karashima, T; Kawada, C; Kurabayashi, A; Nomura, A; Ohtsuki, Y; Shuin, T | 1 |
| Miki, T; Minamide, T | 1 |
| Fukata, S; Hagino, H; Kishimoto, Y; Mizumura, H; Tanishima, S; Teshima, R | 1 |
| Takata, S | 1 |
| Alcalde, RE; Etoh, Y; Kitamura, K; Matsumura, T; Sasaki, A; Suzuki, A; Tanaka, T | 1 |
4 review(s) available for ym 529 and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Geranyltranstransferase; GTP-Binding Proteins; Humans; Imidazoles; Mevalonic Acid; Osteoporosis; Spinal Fractures | 2009 |
[Minodronic acid hydrate as a new therapeutic agent for osteoporosis].
Topics: Animals; Bone Density; Bone Resorption; Clinical Trials, Phase II as Topic; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Osteoporosis, Postmenopausal; Polyisoprenyl Phosphates; Rats; Sesquiterpenes | 2005 |
[Therapeutic agents for disorders of bone and calcium metabolism: Minodronic acid hydrate].
Topics: Animals; Bone Density; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Female; Humans; Imidazoles; Osteoclasts; Osteoporosis; Rats; Spinal Fractures | 2007 |
[New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Drug Design; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Research | 2007 |
2 trial(s) available for ym 529 and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Three years of treatment with minodronate in patients with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Resorption; Calcium, Dietary; Cholecalciferol; Cohort Studies; Combined Modality Therapy; Dietary Supplements; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Incidence; Lumbar Vertebrae; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Time Factors | 2012 |
A comparative study of the effects of daily minodronate and weekly alendronate on upper gastrointestinal symptoms, bone resorption, and back pain in postmenopausal osteoporosis patients.
Topics: Aged; Alendronate; Back Pain; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Diphosphonates; Drug Administration Schedule; Female; Gastrointestinal Tract; Humans; Imidazoles; Osteoporosis, Postmenopausal; Pain Measurement; Peptides; Surveys and Questionnaires | 2013 |
14 other study(ies) available for ym 529 and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bone Resorption; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Etidronic Acid; Humans; Lactates; Organophosphonates; Organophosphorus Compounds; Osteoporosis; Protein Prenylation; rab GTP-Binding Proteins; Risedronic Acid; Stereoisomerism | 2010 |
Inhibition of Autograft Bone Resorption by Antibone Resorptive Agents After Spinal Reconstruction Surgery for Extensive Cervical Chondrosarcoma: A Case Report with a 10-Year Follow-Up.
Topics: Adult; Autografts; Bone Resorption; Bone Transplantation; Cervical Vertebrae; Chondrosarcoma; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Plastic Surgery Procedures; Spinal Neoplasms; Time Factors | 2020 |
Intermittent minodronic acid treatment with sufficient bone resorption inhibition prevents reduction in bone mass and strength in ovariectomized rats with established osteopenia comparable with daily treatment.
Topics: Animals; Biomarkers; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Femur; Imidazoles; Lumbar Vertebrae; Organ Size; Ovariectomy; Rats; Rats, Inbred F344; Weight-Bearing | 2013 |
Minodronic acid suppresses gonadotropin-releasing hormone agonist-induced bone remodeling biomarkers: a retrospective pilot study.
Topics: Adenomyosis; Adult; Biomarkers; Bone Remodeling; Bone Resorption; Buserelin; Diphosphonates; Female; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Leiomyoma; Leuprolide; Middle Aged; Pilot Projects; Retrospective Studies; Uterine Neoplasms | 2016 |
Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors.
Topics: Animals; Autoradiography; Bone Density Conservation Agents; Bone Resorption; Cells, Cultured; Cortical Bone; Diphosphonates; Female; Femur; Imidazoles; Models, Biological; Osteoclasts; Purinergic P2X Receptor Antagonists; Rabbits; Rats; Receptors, Purinergic P2X2; Receptors, Purinergic P2X3 | 2018 |
Changes in urinary excretion of deoxypyridinoline in tail-suspended rats: effects of a bisphosphonate, YH529.
Topics: Amino Acids; Animals; Biomarkers; Bone Resorption; Diphosphonates; Hindlimb Suspension; Imidazoles; Male; Rats; Rats, Wistar; Weightlessness Countermeasures; Weightlessness Simulation | 1998 |
Effects of bisphosphonate on bone metabolism in tail-suspended rats.
Topics: Animals; Bone and Bones; Bone Demineralization, Pathologic; Bone Density; Bone Resorption; Calcium; Diphosphonates; Femur; Hindlimb Suspension; Humerus; Imidazoles; Male; Phosphorus; Rats; Rats, Wistar; Weightlessness Simulation | 1996 |
Administration of bisphosphonate prevents disuse bone atrophy induced by tail suspension.
Topics: Animals; Body Weight; Bone Demineralization, Pathologic; Bone Diseases, Metabolic; Bone Resorption; Calcium; Diphosphonates; Femur; Hindlimb Suspension; Humerus; Imidazoles; Male; Phosphorus; Rats; Rats, Wistar; Sodium Chloride; Weightlessness Simulation | 1997 |
A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Carcinoma, Small Cell; Cell Division; Cytokines; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Humans; Imidazoles; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Kidney Neoplasms; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Lymphocyte Depletion; Lymphokines; Male; Mice; Mice, SCID; Osteolysis; Parathyroid Hormone-Related Protein; Peptide Hormones; Severe Combined Immunodeficiency; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.
Topics: Animals; Body Weight; Bone Resorption; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Gene Expression; Glycoproteins; Imaging, Three-Dimensional; Imidazoles; Interleukin-6; Male; Mandible; Membrane Glycoproteins; Mice; Mice, Inbred C3H; Mouth Neoplasms; Neoplasm Invasiveness; Osteoclasts; Osteoprotegerin; Parathyroid Hormone-Related Protein; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tomography, X-Ray Computed; Tumor Necrosis Factor-alpha | 2005 |
Effect of combination therapy with a novel bisphosphonate, minodronate (YM529), and docetaxel on a model of bone metastasis by human transitional cell carcinoma.
Topics: Acid Phosphatase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Bone Resorption; Carcinoma, Transitional Cell; Cell Line; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Humans; Imidazoles; Immunohistochemistry; In Situ Nick-End Labeling; Isoenzymes; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Proliferating Cell Nuclear Antigen; Tartrate-Resistant Acid Phosphatase; Taxoids; Tibia; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2005 |
Minodronic acid influences receptor activator of nuclear factor kappaB ligand expression and suppresses bone resorption by osteoclasts in rats with collagen-induced arthritis.
Topics: Animals; Arthritis, Experimental; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Models, Animal; Female; Imidazoles; Osteoprotegerin; RANK Ligand; Rats; Rats, Sprague-Dawley | 2007 |
Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Imidazoles; Mice; Mice, Nude; Neoplasm Transplantation; Osteolysis | 1998 |